At the American College of Asthma, Allergy & Immunology (ACAAI) Annual Scientific Meeting, Ionis Pharmaceuticals, Inc. presents positive results from the Phase 2 study of its investigational antisense medicine, donidalorsen (formerly IONIS-PKK-LRx). The Phase 2 study results support the clinical profile of donidalorsen as a potential, best-in-class prophylactic treatment for patients with HAE, and underscore Ionis’ commitment to advancing antisense technology to target the root cause of diseases.
Topline results of the Phase 2 study show that donidalorsen meets its primary and all secondary endpoints, achieving significant reductions in the number of attacks suffered by patients with HAE compared to placebo. These data support advancing donidalorsen into Phase 3 development, which Ionis plans to initiate this year.
(Source: Ionis)
